From the archive
Page 16 of 38 · 905 stories
From the archive
361–384 of 905 articles
Medicare's GLP-1 Bridge Costs $245 a Month. The Break-Even Price Is $150. Nobody Changed the Number.
Medicare's new GLP-1 Bridge Program launched July 1 at a negotiated $245/month per enrollee. A JAMA fiscal model shows net savings begin at $150/month. The $95 gap costs $3.4 billion per year at base-case enrollment, and the program expires five years before generics arrive.
75% of Statin Users Quit Within Five Years. A Single Injection Just Silenced Their Cholesterol Gene for 18 Months.
Scribe Therapeutics' STX-1150 entered the first human trial of epigenetic CRISPR silencing for cardiovascular disease, cutting LDL cholesterol by more than 50% in primates without permanently altering DNA. The compliance math changes everything.
NASA Spent $2 Billion on Satellite Repair and Cancelled It. A Startup Just Did It for $30 Million.
Katalyst Space launched a 399-kilogram spacecraft to rescue a $500 million telescope in 9 months, for 1.5% of what NASA's in-house program burned before it was scrapped.
Three Nuclear Reactors Went Critical in 26 Days. Their Customer Pays $2,000 Per Megawatt-Hour.
Three nuclear startups achieved criticality in June 2026. They aren't repeating NuScale's mistake of competing with solar. The real customer is data centers.
A Drone Boat Rescued Two Downed Pilots Off Oman. For the Price of One Destroyer, the Navy Could Buy 2,200 More.
On June 8, a Saronic Corsair USV pulled two Army aviators from the water near the Strait of Hormuz. The Navy's small USV inventory went from 4 to 500 in two years. The cost math against traditional warships is 2,200 to 1.
Bain Paid $18 Billion for a Chip Company Nobody Wanted. It's Worth $270 Billion Now.
Kioxia's stock has surged 57× from its IPO price in 18 months, turning a deal Bain Capital nearly wrote off into the greatest PE carve-out return in history. The catalyst wasn't luck. It was a structural shift nobody saw coming: AI inference eats NAND, and Kioxia is the only company with next-gen supply.
A $428,000 Cell Therapy Just Got FDA Approval. Its Real Cost to the Healthcare System May Be Half That.
Orca Bio's Tregzi cuts chronic graft-versus-host disease from 44% to 13% in stem cell transplant patients. When you factor in the lifetime cost of managing the disease it prevents, the sticker shock tells only half the story.
Token Prices Fell 98%. Developer AI Bills Rose 100×. The Jevons Paradox Has Arrived.
Microsoft killed its Claude Code licenses after burning through an annual AI budget in months. Uber blew its 2026 AI spend in 120 days. Gartner says AI coding costs will surpass developer salaries by 2028. Here's the math.
The Strongest El Niño Since 1950 Is Forming on a Planet That's Already 1.3°C Warmer. Citigroup Estimates the Bill at $7 Trillion.
India just recorded its 5th driest June since 1901. Indonesia is warning farmers to change planting schedules. And the Niño3.4 index rose 0.3°C in two weeks. When drought hits the countries that grow 55% of the world's rice during a fertilizer shortage caused by the Iran war, the math on the caloric deficit gets ugly fast.
Vertex Has Cured 69 Sickle Cell Patients in 30 Months. There Are 100,000 Left.
The FDA just expanded the world's first CRISPR gene therapy to children as young as two. At 64 patients per year, treating every eligible American would take 336 years.
Qualcomm Promised $15 Billion in Datacenter Revenue by 2029. Its Current Datacenter Revenue Is Zero.
At its June 2026 Investor Day, Qualcomm unveiled a near-memory compute architecture it claims delivers 133 TB/s of 'effective' bandwidth, a 250-core server CPU, and anchor deals with Meta and Microsoft. The physics of that bandwidth claim deserve a closer look.
90,000 Letters of DNA, 150 Molecules, Zero Borrowed Genes. The First Synthetic Cell That Evolves.
University of Minnesota researchers assembled SpudCell from nonliving parts: a 90-kilobase genome that's 83% smaller than the previous minimal cell. It feeds, grows, divides, and exhibits Darwinian selection. It also can't make its own ribosomes.
Ford and GM Wrote Down $27 Billion on EVs. Now They're Converting Those Factories to Chase Tesla's Most Profitable Business.
Detroit burned $27.1B on EVs and is spending $2B to pivot the same factories into grid storage. Tesla already makes 2x the margin on batteries that it does on cars. The math on catching up.
South Korea Just Committed 107% of Its GDP to Memory Chips. The Last Time It Bet This Big, Profits Fell 89% in One Year.
$2.07 trillion from two companies in a country with $1.93 trillion in GDP. At peak profits, payback takes 41 years. And memory is cyclical.
The US Government Bought Equity in 9 Quantum Companies. Their Combined Revenue Wouldn't Cover One F-35 Engine.
$2 billion in CHIPS Act funding for a sector with $169 million in combined revenue. The math is either visionary or insane.
SpaceX Launched 170 Rockets in 2025 and Charged for 43. The IPO Filing Shows Where the Other $2.4 Billion Went.
SpaceX's S-1 reveals three numbers that challenge the bull case: ARPU falling to $66/month, xAI burning $1.44 for every dollar Starlink earns, and a valuation of $218,000 per subscriber.
California Let One Professor Cite Herself 76 Times in a 1,000-Page Math Framework. Then the State Board Passed It Anyway.
A Stanford mathematician read every citation in California's math framework. The papers said the opposite of what the framework claimed. We're open-sourcing the tools to audit yours.
A $36 Million Fusion Startup Just Demonstrated What a $15.5 Billion One Hasn't
Realta Fusion generated electricity from fusion plasma using direct energy conversion. The Q-factor math shows why this matters more than the lightbulb it powered.
Two Generic Drugs That Cost $1 a Day Just Showed the Biggest Survival Benefit in ALS History
PrimeC combines celecoxib and ciprofloxacin into an ALS therapy with a 15-month median survival benefit. An original cost-per-survival-month analysis across every ALS drug reveals a potential 160-fold advantage.
A Single Injection Reversed Muscle Loss in a Disease With Zero Treatments. It Didn't Cut Any DNA.
Epicrispr's EPI-321 is the first epigenetic editing therapy to show muscle mass gain in FSHD patients. An original analysis compares epigenetic editing vs DNA-cutting approaches across cost, safety, and scalability.
A 4-Week Drug Restored Aged Stem Cells Without Fixing What Made Them Old. Their Telomeres Were Still Short.
Telomeric antisense oligonucleotides silenced the damage alarm at short telomeres in old mice without lengthening them. Stem cells competed with young ones. Vaccine responses improved. An original cost analysis reveals the economics.
Britain Cancelled Its Next Destroyer to Build Robot Warships Instead. For the Price of One Type 83, the Royal Navy Could Field 20 Uncrewed Missile Barges.
The UK scrapped the Type 83 destroyer and announced four new classes of uncrewed warships within a £5 billion drone investment. An original cost-per-sensor-day analysis shows the hybrid fleet could deliver 7 to 13 times more patrol coverage per pound.
IBM Packs 100 Billion Transistors on a Fingernail. Its Last Breakthrough, From 2021, Still Isn't in Mass Production.
IBM has demonstrated every major chip node first since 2015 and manufactured zero. A systematic analysis of the widening lab-to-factory gap shows why the 0.7nm nanostack may not reach production until 2031.
Tesla Promised 100 GWh of Batteries by 2023. It Has 18 GWh in 2026. Now It Wants to Build a $119 Billion Chip Fab.
Applying Tesla's Battery Day execution trajectory to Terafab economics shows break-even requires 70%+ fab utilization on Intel's unproven 14A node.
More articles load as you scroll.